People with acute COVID-19 who took the antiviral drug molnupiravir (Lagevrio) reported modest improvements in symptoms, less ...

Molnupiravir treatment for COVID-19 shows modest long-term benefits, reducing symptoms and improving well-being at three and ...

Jynneos, developed in 2019 by Bavarian Nordic, is supposed to be administered as two doses given 28 days apart. A live ...

Molnupiravir has shown to be a promising option for treating feline infectious peritonitis as a first- and second-line ...

A new COVID variant, XEC, has arrived just before fall. The new variant has sprouted from the Omicron variant that developed ...

COVID symptoms can be mild, severe, or nonexistent, according to the CDC—and can appear as late as two weeks after you’ve ...

Today, Wedgewood announces the addition of molnupiravir to its formulary. Originally developed for human viral infections, including COVID-19, molnupiravir has emerged as a promising option for ...

Wedgewood, the nation’s largest provider of compounded veterinary medications, announces the addition of molnupiravir to its ...

Researchers indicate that the vaccine and booster shots should protect against the new variant. Here is what we know about ...